RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SINGLE-DOSE ANTIBIOTIC-PROPHYLAXIS WITH FUSIDIC ACID IN NEUROSURGERY

In neurosurgery, the antibiotic prophylaxis of choice has not yet been determined. The ideal drug should have an appropriate anti-microbial spectrum and favourable pharmacokinetic properties. In addition it should be nontoxic and easy to apply. We therefore conducted in 90 patients a prospective, randomized, placebo-controlled, double-blind trial in clean neurosurgery at increased risk of wound infection using a single pre-operative dose of 500 mg fusidic acid. Fusidic acid is a steroid-like antibiotic with a serum half-life of about 10 hours and excellent activity against grampositive bacteria, including methicillin-resistant staphylococci. The neurosurgical infection rates for craniotomies, posterior fossa surgery and implantation of foreign bodies were 2.4% in the treatment group and 9.1% in the placebo group, respectively. This difference is statistically significant at a 95% confidence level.